Darifenacin
Darifenacin is a muscarinic receptor antagonist used to treat overactive bladder and urinary incontinence. It works by blocking muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and providing relief from urgency, frequency, and urge incontinence.
A bladder-relaxing medication that treats overactive bladder by blocking muscarinic receptors to reduce involuntary bladder contractions.
Key facts at a glance
- ATC
- G04BD10
- RxNorm
- 136198
- Generic
- Darifenacin
- Class
- atc-g04
- Brands
- Enablex
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 7.5mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- not established
- Maximum
- consult physician
- Frequency
- not applicable
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 7.5mg once daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if benefits outweigh potential risks to fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
use only if benefits outweigh potential risks to fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
use only if benefits outweigh potential risks to fetus
regular prenatal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingdiscontinue breastfeeding or avoid drug
darifenacin is excreted in breast milk, avoid use during breastfeeding
monitor infant for anticholinergic effects
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly over 65start at low end of dosing range
use with caution due to increased sensitivity to anticholinergic effects
monitor for cognitive effects, constipation, urinary retention
Use with caution and monitor for adverse effects.
pediatric_age
children under 18not recommended
not approved for use in pediatric patients, safety and efficacy not established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
moderate renal impairmentno dose adjustment required for mild to moderate impairment
use with caution in severe renal impairment
monitor renal function periodically
Use with caution and monitor for adverse effects.
renal_impairment
severe renal impairmentuse lower starting dose
use with caution, consider dose reduction
monitor renal function and for adverse effects
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate hepatic impairmentreduce dose
use with caution, dose should not exceed 7.5 mg daily
monitor liver function and for adverse effects
Use with caution and monitor for adverse effects.
hepatic_impairment
severe hepatic impairmentnot recommended
avoid use in severe hepatic impairment due to significantly increased exposure
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
FDA approval year
FDA approval date for Darifenacin
Drug class
Pharmacological classification
Primary indication
Therapeutic use
Brand name
Commercial brand name
Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency
Competitive muscarinic receptor antagonist that blocks acetylcholine from binding to muscarinic receptors in the detrusor muscle, inhibiting involuntary bladder contractions
May cause anticholinergic side effects such as dry mouth, constipation, and blurred vision; use cautiously in patients with narrow-angle glaucoma, urinary retention, or severe hepatic impairment; efficacy may be reduced in CYP2D6 poor metabolizers
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy